Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease.

The global market for Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by region & country, by Type, and by Application.

The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment.

Market Segmentation

Scope of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment - Market Report

Report Metric	Details
Report Name	Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment - Market
CAGR	5%
Segment by Type:	Transthyretin Stabilizers Nonsteroidal Anti-inflammatory Drugs (NSAID) RNAi Therapy Others
Segment by Application	Hereditary Transthyretin Amyloidosis (hATTR) Wild Type Transthyretin Amyloidosis (wtATTR)
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer Inc, GlaxoSmithKline Plc, Eidos Therapeutics, Ionis Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Prothena Corporation Plc, Intellia Therapeutics, Inc, Corino Therapeutics, Inc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment - Market report?

Ans: The main players in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment - Market are Pfizer Inc, GlaxoSmithKline Plc, Eidos Therapeutics, Ionis Pharmaceuticals, Inc, Alnylam Pharmaceuticals, Prothena Corporation Plc, Intellia Therapeutics, Inc, Corino Therapeutics, Inc

What are the Application segmentation covered in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment - Market report?

Ans: The Applications covered in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment - Market report are Hereditary Transthyretin Amyloidosis (hATTR), Wild Type Transthyretin Amyloidosis (wtATTR)

What are the Type segmentation covered in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment - Market report?

Ans: The Types covered in the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment - Market report are Transthyretin Stabilizers, Nonsteroidal Anti-inflammatory Drugs (NSAID), RNAi Therapy, Others

1 Market Overview

1.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Introduction

1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast

1.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends & Drivers

1.3.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Trends

1.3.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers & Opportunity

1.3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges

1.3.4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players Revenue Ranking (2023)

2.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Company (2019-2024)

2.3 Key Companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Manufacturing Base Distribution and Headquarters

2.4 Key Companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Offered

2.5 Key Companies Time to Begin Mass Production of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment

2.6 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Competitive Analysis

2.6.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Transthyretin Stabilizers

3.1.2 Nonsteroidal Anti-inflammatory Drugs (NSAID)

3.1.3 RNAi Therapy

3.1.4 Others

3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type

3.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, by Type (2019-2030)

3.2.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hereditary Transthyretin Amyloidosis (hATTR)

4.1.2 Wild Type Transthyretin Amyloidosis (wtATTR)

4.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application

4.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, by Application (2019-2030)

4.2.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Region

5.1.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Region (2019-2024)

5.1.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Region (2025-2030)

5.1.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

5.2.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

5.3.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

5.4.2 Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

5.5.2 South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

5.6.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value

6.3 United States

6.3.1 United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

6.3.2 United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

6.4.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

6.5.2 China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

6.5.3 China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

6.6.2 Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

6.7.2 South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

6.8.2 Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019-2030

6.9.2 India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

6.9.3 India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Pfizer Inc

7.1.1 Pfizer Inc Profile

7.1.2 Pfizer Inc Main Business

7.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

7.1.4 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$ Million) & (2019-2024)

7.1.5 Pfizer Inc Recent Developments

7.2 GlaxoSmithKline Plc

7.2.1 GlaxoSmithKline Plc Profile

7.2.2 GlaxoSmithKline Plc Main Business

7.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

7.2.4 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$ Million) & (2019-2024)

7.2.5 GlaxoSmithKline Plc Recent Developments

7.3 Eidos Therapeutics

7.3.1 Eidos Therapeutics Profile

7.3.2 Eidos Therapeutics Main Business

7.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

7.3.4 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$ Million) & (2019-2024)

7.3.5 Ionis Pharmaceuticals, Inc Recent Developments

7.4 Ionis Pharmaceuticals, Inc

7.4.1 Ionis Pharmaceuticals, Inc Profile

7.4.2 Ionis Pharmaceuticals, Inc Main Business

7.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

7.4.4 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$ Million) & (2019-2024)

7.4.5 Ionis Pharmaceuticals, Inc Recent Developments

7.5 Alnylam Pharmaceuticals

7.5.1 Alnylam Pharmaceuticals Profile

7.5.2 Alnylam Pharmaceuticals Main Business

7.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

7.5.4 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$ Million) & (2019-2024)

7.5.5 Alnylam Pharmaceuticals Recent Developments

7.6 Prothena Corporation Plc

7.6.1 Prothena Corporation Plc Profile

7.6.2 Prothena Corporation Plc Main Business

7.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

7.6.4 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$ Million) & (2019-2024)

7.6.5 Prothena Corporation Plc Recent Developments

7.7 Intellia Therapeutics, Inc

7.7.1 Intellia Therapeutics, Inc Profile

7.7.2 Intellia Therapeutics, Inc Main Business

7.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

7.7.4 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$ Million) & (2019-2024)

7.7.5 Intellia Therapeutics, Inc Recent Developments

7.8 Corino Therapeutics, Inc

7.8.1 Corino Therapeutics, Inc Profile

7.8.2 Corino Therapeutics, Inc Main Business

7.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

7.8.4 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (US$ Million) & (2019-2024)

7.8.5 Corino Therapeutics, Inc Recent Developments

8 Industry Chain Analysis

8.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industrial Chain

8.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Model

8.5.2 Sales Channel

8.5.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Pfizer Inc

GlaxoSmithKline PLC

Eidos Therapeutics

Ionis Pharmaceuticals Inc

Alnylam Pharmaceuticals

Prothena Corporation Plc

Intellia Therapeutics Inc

Corino Therapeutics, Inc

List of Tables

Table 1. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends

Table 2. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers & Opportunity

Table 3. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges

Table 4. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints

Table 5. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Type

Table 9. Key Companies Time to Begin Mass Production of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment

Table 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Region (2019-2024) & (%)

Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, (2025-2030) & (US$ Million)

Table 31. Pfizer Inc Basic Information List

Table 32. Pfizer Inc Description and Business Overview

Table 33. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

Table 34. Revenue (US$ Million) in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business of Pfizer Inc (2019-2024)

Table 35. Pfizer Inc Recent Developments

Table 36. GlaxoSmithKline Plc Basic Information List

Table 37. GlaxoSmithKline Plc Description and Business Overview

Table 38. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

Table 39. Revenue (US$ Million) in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business of GlaxoSmithKline Plc (2019-2024)

Table 40. GlaxoSmithKline Plc Recent Developments

Table 41. Eidos Therapeutics Basic Information List

Table 42. Eidos Therapeutics Description and Business Overview

Table 43. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

Table 44. Revenue (US$ Million) in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business of Eidos Therapeutics (2019-2024)

Table 45. Eidos Therapeutics Recent Developments

Table 46. Ionis Pharmaceuticals, Inc Basic Information List

Table 47. Ionis Pharmaceuticals, Inc Description and Business Overview

Table 48. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

Table 49. Revenue (US$ Million) in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business of Ionis Pharmaceuticals, Inc (2019-2024)

Table 50. Ionis Pharmaceuticals, Inc Recent Developments

Table 51. Alnylam Pharmaceuticals Basic Information List

Table 52. Alnylam Pharmaceuticals Description and Business Overview

Table 53. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

Table 54. Revenue (US$ Million) in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business of Alnylam Pharmaceuticals (2019-2024)

Table 55. Alnylam Pharmaceuticals Recent Developments

Table 56. Prothena Corporation Plc Basic Information List

Table 57. Prothena Corporation Plc Description and Business Overview

Table 58. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

Table 59. Revenue (US$ Million) in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business of Prothena Corporation Plc (2019-2024)

Table 60. Prothena Corporation Plc Recent Developments

Table 61. Intellia Therapeutics, Inc Basic Information List

Table 62. Intellia Therapeutics, Inc Description and Business Overview

Table 63. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

Table 64. Revenue (US$ Million) in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business of Intellia Therapeutics, Inc (2019-2024)

Table 65. Intellia Therapeutics, Inc Recent Developments

Table 66. Corino Therapeutics, Inc Basic Information List

Table 67. Corino Therapeutics, Inc Description and Business Overview

Table 68. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Products, Services and Solutions

Table 69. Revenue (US$ Million) in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business of Corino Therapeutics, Inc (2019-2024)

Table 70. Corino Therapeutics, Inc Recent Developments

Table 71. Key Raw Materials Lists

Table 72. Raw Materials Key Suppliers Lists

Table 73. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Downstream Customers

Table 74. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Distributors List

Table 75. Research Programs/Design for This Report

Table 76. Key Data Information from Secondary Sources

Table 77. Key Data Information from Primary Sources

Table 78. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Picture

Figure 2. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 4. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Report Years Considered

Figure 5. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2023

Figure 7. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Transthyretin Stabilizers Picture

Figure 9. Nonsteroidal Anti-inflammatory Drugs (NSAID) Picture

Figure 10. RNAi Therapy Picture

Figure 11. Others Picture

Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 13. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value Market Share by Type, 2023 & 2030

Figure 14. Product Picture of Hereditary Transthyretin Amyloidosis (hATTR)

Figure 15. Product Picture of Wild Type Transthyretin Amyloidosis (wtATTR)

Figure 16. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value Market Share by Application, 2023 & 2030

Figure 18. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 19. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 20. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 21. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 22. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 23. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 24. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 25. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 26. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 27. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 28. Key Countries/Regions Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value (%), (2019-2030)

Figure 29. United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 30. United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 31. United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 32. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 33. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 34. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 35. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 36. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 37. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 38. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 39. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 40. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 41. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 42. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 43. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 44. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 45. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 46. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 47. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 48. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 49. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 50. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industrial Chain

Figure 51. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Manufacturing Cost Structure

Figure 52. Channels of Distribution (Direct Sales, and Distribution)

Figure 53. Bottom-up and Top-down Approaches for This Report

Figure 54. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions